NCT04925141 2021-06-14A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 4 Completed62 enrolled
NCT01660906 2016-11-22Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibBristol-Myers SquibbPhase 4 Completed39 enrolled 14 charts